Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
Clostridium difficile infection
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "Clostridium difficile infection" in MCE Product Catalog:
7
4
4 Cited Publications
Synonyms: ACX-362E; GLS-362E
Target:
Research Areas:
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .
1
1 Cited Publications
Cat. No.: HY-P9929
CAS No.: 1246264-45-8
Synonyms: BLA761046; MBL-CDB1; MDX-1388
1
Target:
Research Areas:
CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .
Target:
Synonyms: Reutericycline
Category:
Infection Microorganisms Antibiotics Disease Research Antibacterial Disease Research Fields Other Antibiotics
Target:
Synonyms: KRM-1648; ABI-1648
Target:
Research Areas:
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .
Target:
Research Areas:
Betamipron (N-benzoyl-β-alanine) is a carbapenem β-lactam antibiotic with antibacterial activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. Betamipron can target and inhibit renal organic anion transporters, alleviate renal injury caused by Cisplatin (HY-17394), without interfering with the biological activity of cisplatin. Betamipron is often used in combination with panipenem, which can attenuate the renal effects induced by panipenem and slightly promote the proliferation of Clostridium difficile in the cecum. Betamipron can be used in studies related to renal injury and bacterial infection .
Cat. No.: HY-17580R
CAS No.: 873857-62-6
Synonyms: OPT-80 (Standard); PAR-101 (Standard)
Cat. No.: HY-128357A
CAS No.: 1275582-98-3
Synonyms: ACX-362E hydrochloride; GLS-362E hydrochloride
Target:
Research Areas:
Ibezapolstat hydrochloride is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat hydrochloride is developed for the research of C. difficile infection(CDI) .
Target:
Research Areas:
Betamipron (Standard) is the analytical standard of Betamipron (HY-B1127). This product is intended for research and analytical applications. Betamipron (N-benzoyl-β-alanine) is a carbapenem β-lactam antibiotic with antibacterial activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. Betamipron can target and inhibit renal organic anion transporters, alleviate renal injury caused by Cisplatin (HY-17394), without interfering with the biological activity of cisplatin. Betamipron is often used in combination with panipenem, which can attenuate the renal effects induced by panipenem and slightly promote the proliferation of Clostridium difficile in the cecum. Betamipron can be used in studies related to renal injury and bacterial infection .
Cat. No.: HY-105099R
CAS No.: 129791-92-0
Synonyms: KRM-1648 (Standard); ABI-1648 (Standard)
Research Areas:
Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].
Cat. No.: HY-138135
CAS No.: 1030825-28-5
Synonyms: Fidaxomicin metabolite OP-1118
OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739) .
Cat. No.: HY-17580S1
Synonyms: OPT-80-d6; PAR-101-d6
Cat. No.: HY-182464
CAS No.: 893603-33-3
Target:
DABMA is a TMEM175 channel activator with a human EC50 of 17.9 μM. DABMA directly increases TMEM175 channel current via interaction with intracellular, transmembrane, or endosomal lumen-associated domains, and does not alter TMEM175 mRNA or protein levels. DABMA delays endolysosomal substrate degradation, modulates endolysosomal trafficking, increases acidic organelle accumulation, induces cholesterol accumulation and altered late endosome morphology. DABMA can be used for the research of coronavirus disease, Clostridium difficile infection, Pseudomonas aeruginosa infection, rabies, and influenza virus infection .
Cat. No.: HY-116880
CAS No.: 2092352-48-0
Target:
Research Areas:
DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
